| 1.29 0.08 (6.61%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.72  |
1-year : | 1.93 |
| Resists | First : | 1.47 |
Second : | 1.65 |
| Pivot price | 1.33 |
|||
| Supports | First : | 1.17 | Second : | 0.98 |
| MAs | MA(5) : | 1.24 |
MA(20) : | 1.36 |
| MA(100) : | 1.52 |
MA(250) : | 1.64 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 13.9 |
D(3) : | 8.3 |
| RSI | RSI(14): 41.7 |
|||
| 52-week | High : | 2.59 | Low : | 0.89 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PSNL ] has closed above bottom band by 35.8%. Bollinger Bands are 49.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.31 - 1.32 | 1.32 - 1.32 |
| Low: | 1.19 - 1.19 | 1.19 - 1.2 |
| Close: | 1.28 - 1.29 | 1.29 - 1.3 |
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
Fri, 19 Apr 2024
Market Cool On Personalis, Inc.'s (NASDAQ:PSNL) Revenues Pushing Shares 25% Lower - Simply Wall St
Fri, 19 Apr 2024
Personalis (NASDAQ:PSNL) adds US$65m to market cap in the past 7 days, though investors from a year ago are still ... - Yahoo Movies UK
Thu, 11 Apr 2024
Needham & Company LLC Reiterates "Buy" Rating for Personalis (NASDAQ:PSNL) - MarketBeat
Tue, 19 Mar 2024
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Sat, 02 Mar 2024
Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 31% Yet They're Still Not Telling The Full Story - Simply Wall St
Thu, 29 Feb 2024
Personalis, Inc. (NASDAQ:PSNL) Q4 2023 Earnings Call Transcript - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 51 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 58.1 (%) |
| Shares Short | 1,080 (K) |
| Shares Short P.Month | 914 (K) |
| EPS | -2.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.55 |
| Profit Margin | -147.4 % |
| Operating Margin | -101.4 % |
| Return on Assets (ttm) | -23.3 % |
| Return on Equity (ttm) | -62.4 % |
| Qtrly Rev. Growth | 17.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.43 |
| EBITDA (p.s.) | -1.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -56 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -0.58 |
| PEG Ratio | 0 |
| Price to Book value | 0.5 |
| Price to Sales | 0.89 |
| Price to Cash Flow | -1.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|